UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

ISI Group maintained Hologic

with a Strong Buy rating and raised the price target from $25.50 to $27.00. ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00." Hologic closed at $23.25 on Monday.